A pivotal chapter in the story of drug discovery for NF2-related schwannomatosis has been written – both figuratively and literally – with a new publication highlighting the critical role of collaboration in the journey of Brigatinib, a drug now offering hope to patients with this rare condition. The chapter, co-authored by a multidisciplinary team of researchers including Dr. Annette Bakker, CEO of the Children’s Tumor Foundation, underscores the groundbreaking work that made Brigatinib a reality for NF2-SWN. |